NICE recommends Roche’s atezolizumab via CDF for bladder cancer
The UK National Institute for Health and Care Excellence (NICE) has recommended the use of Roche’s new immunotherapy, atezolizumab,…
Nancy Victor
All Articles
BioGeneration Ventures closes third fund BGV III at €82m
Netherlands-based venture capital company BioGeneration Ventures (BGV) has confirmed the final closing of its third fund, BGV III, at…